Pops: merger will "transform" Alkermes-EDT into "fully integrated company"
This article was originally published in Scrip
Executive Summary
The merger of Alkermes with Elan Drug Technologies (EDT) – subject to a shareholder vote in September 2011 - will result in the perception of Alkermes as a drug delivery company to change completely, Alkermes' CEO Richard Pops told Scrip. "The transaction will have the effect of significantly accelerating the business plan we have been looking at for the past few years," he explained. "We have been using our drug delivery partnerships as a stepping stone on the way to becoming a fully integrated company with an innovative pipeline of products." In addition, combining the two companies will be "financially transformative… When we put these two together, there will be very few comparable companies".
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.